DK3826639T3 - Optimeret dosering af diaminophenothiaziner i populationer - Google Patents

Optimeret dosering af diaminophenothiaziner i populationer Download PDF

Info

Publication number
DK3826639T3
DK3826639T3 DK19752425.9T DK19752425T DK3826639T3 DK 3826639 T3 DK3826639 T3 DK 3826639T3 DK 19752425 T DK19752425 T DK 19752425T DK 3826639 T3 DK3826639 T3 DK 3826639T3
Authority
DK
Denmark
Prior art keywords
diaminophenothiazines
populations
optimized dosing
dosing
optimized
Prior art date
Application number
DK19752425.9T
Other languages
English (en)
Inventor
Claude Michel Wischik
Björn Olaf Schelter
Helen Christine Shiells
Original Assignee
Wista Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1812193.9A external-priority patent/GB201812193D0/en
Priority claimed from GBGB1909458.0A external-priority patent/GB201909458D0/en
Application filed by Wista Lab Ltd filed Critical Wista Lab Ltd
Application granted granted Critical
Publication of DK3826639T3 publication Critical patent/DK3826639T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A23L33/29—Mineral substances, e.g. mineral oils or clays
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Botany (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK19752425.9T 2018-07-26 2019-07-18 Optimeret dosering af diaminophenothiaziner i populationer DK3826639T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1812193.9A GB201812193D0 (en) 2018-07-26 2018-07-26 Optimised dosage of diaminophenothiazines in populations
GBGB1909458.0A GB201909458D0 (en) 2019-07-01 2019-07-01 Optimised dosage of diaminophenothiazines in populations
PCT/EP2019/069428 WO2020020751A1 (en) 2018-07-26 2019-07-18 Optimised dosage of diaminophenothiazines in populations

Publications (1)

Publication Number Publication Date
DK3826639T3 true DK3826639T3 (da) 2024-09-23

Family

ID=67587720

Family Applications (3)

Application Number Title Priority Date Filing Date
DK24161602.8T DK4385512T3 (da) 2018-07-26 2019-07-18 Optimeret dosering af diaminophenothiaziner i populationer
DK19752425.9T DK3826639T3 (da) 2018-07-26 2019-07-18 Optimeret dosering af diaminophenothiaziner i populationer
DK24161558.2T DK4364801T3 (da) 2018-07-26 2019-07-18 Optimeret dosering af diaminophenothiaziner i populationer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK24161602.8T DK4385512T3 (da) 2018-07-26 2019-07-18 Optimeret dosering af diaminophenothiaziner i populationer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK24161558.2T DK4364801T3 (da) 2018-07-26 2019-07-18 Optimeret dosering af diaminophenothiaziner i populationer

Country Status (19)

Country Link
US (3) US12280061B2 (da)
EP (3) EP4385512B1 (da)
JP (2) JP7465861B2 (da)
KR (1) KR20210038586A (da)
CN (1) CN112805008A (da)
AU (2) AU2019308873B2 (da)
BR (1) BR112021000802A2 (da)
CA (1) CA3106152A1 (da)
DK (3) DK4385512T3 (da)
ES (3) ES3060453T3 (da)
FI (3) FI4385512T3 (da)
HR (3) HRP20260059T1 (da)
IL (1) IL280361B2 (da)
MX (2) MX2021000894A (da)
PL (2) PL3826639T3 (da)
PT (3) PT4364801T (da)
SG (1) SG11202100333XA (da)
SI (3) SI4364801T1 (da)
WO (1) WO2020020751A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101511803B (zh) 2006-07-11 2012-10-31 维斯塔实验室有限公司 二氨基吩噻嗪*化合物的合成和/或纯化方法
PT3487505T (pt) 2016-07-25 2023-06-07 Wista Lab Ltd Administração e dosagem de diaminofenotiazinas
JP7465861B2 (ja) 2018-07-26 2024-04-11 ウィスタ ラボラトリーズ リミテッド 集団におけるジアミノフェノチアジンの最適化投与
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions
JP2023525512A (ja) * 2020-05-05 2023-06-16 ウィスタ ラボラトリーズ リミテッド Covid-19の治療で使用されるメチルチオニニウム化合物
GB202006659D0 (en) 2020-05-05 2020-06-17 Wista Lab Ltd Therapeutic treatments
EP4146225B1 (en) * 2020-05-05 2024-10-09 WisTa Laboratories Ltd. Methylthioninium compounds for use in the treatment of hypoxemia
CA3231484A1 (en) 2021-10-01 2023-04-06 Qinwen Mao Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy
CA3257856A1 (en) 2022-05-31 2023-12-07 Wista Laboratories Ltd. TREATMENT OF NEURODEGENERATIVE DISORDERS USING COMPOUNDS CONTAINING METHYLTHIONINIUM (MT)
EP4590275A1 (en) 2022-09-21 2025-07-30 WisTa Laboratories Ltd. Novel formulations and vehicles
KR20250154422A (ko) 2023-03-03 2025-10-28 타우알엑스 쎄라퓨틱스 매니지먼트 리미티드 미세혈관 뇌질환 치료를 위한 디아미노페노티아진

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
EP1509232B1 (en) 2002-05-31 2008-11-19 H. Lundbeck A/S A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
ES2409683T3 (es) 2004-09-23 2013-06-27 Wista Laboratories Ltd. Procedimientos de síntesis química y purificación de compuestos de diaminofenotiazinio que incluyen cloruro de metiltioninio (CMT)
DK2004155T3 (da) 2006-03-29 2018-04-30 Wista Lab Ltd Inhibitorer af protein-aggregation
CN104606199B (zh) 2006-03-29 2022-09-13 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物盐及其用途
DK2001556T3 (da) 2006-03-29 2014-11-10 Wista Lab Ltd Thioninium-forbindelser og anvendelse deraf
CN101511803B (zh) 2006-07-11 2012-10-31 维斯塔实验室有限公司 二氨基吩噻嗪*化合物的合成和/或纯化方法
PL2167095T3 (pl) 2007-06-19 2019-11-29 Wista Lab Ltd Związki fenotiazynowe do leczenia łagodnych zaburzeń poznawczych
DK2205245T3 (da) 2007-10-03 2015-09-28 Wista Lab Ltd Terapeutisk anvendelse af diaminophenothiaziner
EP2227766A2 (en) 2007-11-05 2010-09-15 Wista Laboratories Ltd. Systems for clinical trials
WO2010078659A1 (en) 2009-01-12 2010-07-15 Foster Health Inc. Compositions and methods for nutritional prevention and treatment of alzheimer's-associated conditions
WO2010104375A1 (en) * 2009-03-12 2010-09-16 N.V. Nutricia Stigmasterol for the treatment of alzheimer's disease
BR112012006626B8 (pt) 2009-09-24 2021-05-25 Wista Lab Ltd processo para a preparação da forma a pentahidratada e método da secagem da forma a pentahidratada de mtc
DE102010062810B4 (de) 2010-09-07 2014-03-13 Immungenetics Ag 2-(R2-Thio)-10-[3-(4-R1-piperazin-1-yl)propyl]-10H-phenothiazine zur Behandlung neurodegenerativer Erkrankungen ausgewählt aus beta-Amyloidopathien und alpha-Synucleinopathien
CA2827027C (en) 2011-02-11 2019-06-04 Wista Laboratories Ltd. Phenothiazine diaminium salts and their use
DK3258938T3 (da) * 2015-02-17 2021-02-01 Univ Arizona State Phenothiazinanaloger som mitokondrie terapeutiske midler
PT3487505T (pt) 2016-07-25 2023-06-07 Wista Lab Ltd Administração e dosagem de diaminofenotiazinas
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
GB201621817D0 (en) 2016-12-21 2017-02-01 Wista Lab Ltd Methods of chemical synthesis
JP7465861B2 (ja) 2018-07-26 2024-04-11 ウィスタ ラボラトリーズ リミテッド 集団におけるジアミノフェノチアジンの最適化投与
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions
GB201909454D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Enhancers
GB201909506D0 (en) 2019-07-02 2019-08-14 Wista Lab Ltd Synaptopathies

Also Published As

Publication number Publication date
US12280061B2 (en) 2025-04-22
SI3826639T1 (sl) 2025-01-31
JP7465861B2 (ja) 2024-04-11
PT3826639T (pt) 2024-10-09
MX2021000894A (es) 2021-03-31
EP3826639A1 (en) 2021-06-02
FI3826639T3 (fi) 2024-10-30
AU2019308873A1 (en) 2021-02-04
JP2021532092A (ja) 2021-11-25
EP4364801A3 (en) 2024-07-10
MX2023009856A (es) 2023-08-29
HRP20260059T1 (hr) 2026-02-27
PL4364801T3 (pl) 2026-04-27
JP7763890B2 (ja) 2025-11-04
SG11202100333XA (en) 2021-02-25
US20230115931A1 (en) 2023-04-13
DK4364801T3 (da) 2025-12-22
SI4385512T1 (sl) 2026-03-31
FI4364801T3 (fi) 2026-01-12
CA3106152A1 (en) 2020-01-30
AU2019308873B2 (en) 2025-03-20
EP3826639B1 (en) 2024-08-21
IL280361A (en) 2021-03-01
HRP20251694T1 (hr) 2026-02-27
AU2025204524A1 (en) 2025-07-03
EP4385512B1 (en) 2025-12-03
KR20210038586A (ko) 2021-04-07
EP4364801A2 (en) 2024-05-08
WO2020020751A1 (en) 2020-01-30
IL280361B2 (en) 2024-07-01
ES2989458T3 (es) 2024-11-26
CN112805008A (zh) 2021-05-14
DK4385512T3 (da) 2026-02-09
PT4364801T (pt) 2026-01-26
FI4385512T3 (fi) 2026-01-12
US20210236509A1 (en) 2021-08-05
HRP20241360T1 (hr) 2024-12-20
EP4385512A1 (en) 2024-06-19
US20250302843A1 (en) 2025-10-02
ES3060453T3 (en) 2026-03-26
JP2024096123A (ja) 2024-07-12
US12263175B2 (en) 2025-04-01
SI4364801T1 (sl) 2026-03-31
ES3060455T3 (en) 2026-03-26
PL3826639T3 (pl) 2025-01-07
IL280361B1 (en) 2024-03-01
PT4385512T (pt) 2026-01-23
EP4364801B1 (en) 2025-11-12
BR112021000802A2 (pt) 2021-04-13

Similar Documents

Publication Publication Date Title
DK4364801T3 (da) Optimeret dosering af diaminophenothiaziner i populationer
DK3735147T3 (da) Rygsæk
PL3886665T3 (pl) Jednostka dozująca
DK3512850T3 (da) Inhibitorer af menin-mll-interaktionen
DK3468966T3 (da) Inhibitorer af menin-mll-interaktionen
PL3443009T3 (pl) Przeciwciała i kompozycje anty-tim-3
PL3653221T3 (pl) Przeciwciała anty-pvrig i sposoby ich zastosowania
PL3274370T3 (pl) Przeciwciała anty-ceacam6 i ich zastosowania
SI3350157T1 (sl) Sestave za doziranje terapevtskih sredstev v celice
DK3193931T3 (da) Neutralisering af hæmmende veje i lymfocytter
DK3328414T3 (da) Sammensætning til anvendelse i fremme af sårheling
DK3166911T3 (da) Inkorporering af biologiske midler i gødning
DK3297653T3 (da) Behandling af postbariatrisk hypoglykæmi med glp-1-antagonister
DK3350334T3 (da) Udtryk af rekombinante proteiner i trichoplusia ni pupper
IL269559A (en) Stable multispecific antibodies
DK3094322T3 (da) Administration af tasimelteon i fastende tilstand
DK3844162T3 (da) Hæmmere af alfa-v-beta6-integrin
DK3204767T3 (da) Proteins anvendelighed i forudsigelsen af in vivo-effekter
EP3137649C0 (en) METALLIZATION OF SURFACES
DK3247687T3 (da) Anvendelse af nivelleringsforbindelse
DK3155422T4 (da) Demaskering af endotoksiner i opløsning
DK3242680T3 (da) Interleukin-1-receptorantagonist til anvendelse i behandling af cystitis
DK3183359T3 (da) Effektiv valg af rekombinante proteiner
ES1226030Y (es) Jarra
EP3844572B1 (fr) Echappement horloger